Novavax, Inc. announced that the protein-based Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373), had received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to provide a first booster dose of at least six months after completion of primary vaccination with an authorized or approved COVID-19 vaccine to individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate.
Read More
